Psoriatic Arthritis Leukopak
LeukoCore Psoriatic Arthritis Leukopak contains concentrated immune cells from donors with clinically confirmed psoriatic arthritis, collected via apheresis. Psoriatic arthritis is a seronegative, IL-23/IL-17-driven spondyloarthritis rather than an autoantibody-mediated disease. Ideal for Th17 and innate-like lymphocyte immunophenotyping, rare-subset sorting, IL-17/IL-23 functional assays, and single-cell studies. Matched healthy controls available.
High-Yield LeukoCore Psoriatic Arthritis Leukopaks for Immune-Mediated Inflammatory Disease Research
LeukoCore Psoriatic Arthritis Leukopak biospecimens are collected from IRB-consented donors clinically diagnosed with psoriatic arthritis through IRB-approved apheresis procedures, then processed and shipped within 24 hours of collection. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs). Psoriatic arthritis is a seronegative, immune-mediated inflammatory disease of the IL-23/IL-17 axis – it is not autoantibody-driven – and high-yield leukocyte material supports the cellular immunology that this mechanism demands.
Psoriatic Arthritis Immunology and Why a Leukopak
- Psoriatic arthritis belongs to the seronegative spondyloarthritis family. Rheumatoid factor and anti-citrullinated protein antibodies are characteristically absent, so the rheumatoid arthritis autoantibody framework does not apply and should not be imported.
- The central pathogenic pathway runs from IL-23 through Th17 and related innate-like lymphocyte populations to IL-17A, IL-17F, and IL-22, with TNF contributing throughout. This is validated by the efficacy of IL-17, IL-23, and TNF inhibitors in the disease.
- Characteristic lesions include enthesitis at tendon and ligament insertions, dactylitis, nail disease, and both bone erosion and new bone formation – a combination of destructive and proliferative change that distinguishes it from rheumatoid arthritis.
- HLA-B27 is associated particularly with axial involvement, while HLA-C*06:02 associates with the cutaneous psoriasis phenotype, and the two patterns can be used to stratify donors.
- Innate-like and tissue-homing lymphocyte subsets – including gamma-delta T cells, mucosal-associated invariant T cells, and CCR6+ Th17 populations – are present at low frequency in blood, which is precisely why apheresis-scale material is required to isolate and study them.
- Leukopaks deliver the cell numbers needed for multi-arm functional assays, rare-subset sorting, and single-cell studies that cannot be powered from a standard venous draw.
Donor Stratification Available
- Disease pattern: peripheral oligoarticular or polyarticular versus axial involvement
- Presence of enthesitis, dactylitis, and nail psoriasis
- Concomitant cutaneous psoriasis and its severity where documented
- Treatment exposure: bDMARD-naive, anti-TNF, anti-IL-17, anti-IL-23/IL-12-23, or JAK inhibitor treated; conventional DMARD background
- Disease activity at collection and disease duration
- HLA-B27 status where typing is available; age band and sex
- Matched healthy controls available
Product Features
- Research Use Only (RUO) human leukopaks
- Clinically confirmed psoriatic arthritis donors
- High cell yield for large-scale studies
- Processed and shipped within 24 hours of collection
- Fresh or cryopreserved options available
- IRB-approved and ethically sourced
- Infectious disease testing
- HLA-A typing
- Screen donors with LeukoLot™
De-identified Donor Data
- Verified psoriatic arthritis diagnosis from healthcare providers
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported medication history and allergies
- Relevant clinical data, including disease pattern, activity, and treatment history where documented
Applications
- Immunophenotyping of Th17, Tc17, gamma-delta T-cell, and MAIT populations by spectral or conventional flow cytometry
- Cell sorting of rare tissue-homing and innate-like lymphocyte subsets
- IL-23/IL-17 axis functional assays, including stimulation and cytokine release profiling
- Ex vivo drug screening and mechanism-of-action work for IL-17, IL-23, TNF, and JAK-targeted agents
- Single-cell RNA sequencing, CITE-seq, and TCR repertoire analysis
- Osteoclast differentiation assays from donor-derived monocytes to model bone erosion
- Biomarker discovery and validation for treatment response and disease activity
- Large matched cell lot banking for multi-site or longitudinal spondyloarthritis studies
Other Psoriatic Arthritis Specimen Types
- Psoriatic Arthritis PBMC
- Psoriatic Arthritis Plasma
- Psoriatic Arthritis Serum
- Psoriatic Arthritis Whole Blood
- Psoriatic Arthritis Synovial Fluid
- Psoriatic Arthritis Skin Punch Biopsy
- Psoriatic Arthritis Bulk Plasma
Compliance and Quality Assurance
- Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
- HIPAA-compliant handling of donor information
- Rigorous donor screening and documentation
Ordering & Customization
Psoriatic Arthritis Leukopak is available fresh or cryopreserved. For pricing, international shipping, or regulatory documentation, please contact learnmore@sanguinebio.com to confirm regional compliance and shipping availability. Need a different condition, or want to check current availability across our full inventory? Visit our human leukopak page to browse other disease-state options and live stock status.
Protocols & Documentation
-
Download
Leukopak Cryopreservation
Standard operating procedure for cryopreserving leukopak units with controlled freezing and post-thaw viability targets.
-
Download
Leukopak Thawing
Validated thawing workflow for cryopreserved leukopaks to maximize recovery while maintaining sterility and chain of custody.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Leukopak
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Leukopak cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.